Chronic Kidney Disease (CKD) induced Hyperparathyroidism (HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) – Epidemiology Forecast to 2030
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Diagnosed prevalent cases of chronic kidney disease (CKD) in the seven major markets (7MM*) combined is expected to increase from 8.57 million cases in 2020 to 9.44 million in 2030, at an annual growth rate (AGR) of 1.02%, according to GlobalData, a leading data and analytics company.
Of the 7MM, the diagnosed prevalent cases of CKD in the US are expected to increase at an AGR of 1.59% between 2020 and 2030, followed by Spain (1.51%), and France (1.19%).
The major drivers for the spike in the diagnosed prevalent cases of CKD in the US and the 7MM combined is attributable to the aging population combined with population genetics and other risk factors. Factors such as race, gender, age and family history are highly linked to CKD. Moreover, smoking, obesity, hypertension and diabetes mellitus can also increase the risk for CKD.
Suneedh Manthri, Associate Project Manager of Epidemiology at GlobalData, comments: “CKD is largely an asymptomatic condition that damages the kidneys and leads to the loss of kidney function over time. Currently, there is no cure for CKD; however, treatments can slow the progression of the disease. In the advanced stages of the disease CKD patients are advised to undergo renal replacement therapy (RRT) when the kidneys fail. Another way to reduce the burden of CKD would be early intervention. In order to achieve this, it is important to identify individuals with increased risk for CKD. Determining serum creatinine levels and urinalysis in patients with CKD risk will usually be sufficient for initial screening.”
*7MM: The US, France, Germany, Italy, Spain, the UK, and Japan
Scope
Chronic kidney disease (CKD), or chronic renal disease, is a condition characterized by a gradual loss of kidney function over time. In the early stages, CKD is a largely asymptomatic condition that damages the kidneys and leads to the loss of kidney function over time (Centers for Disease Control and Prevention, 2019). As the disease progresses, the symptoms worsen and eventually lead to kidney failure (Centers for Disease Control and Prevention, 2019). The glomerular filtration rate (GFR), a key measure of kidney function, is determined by the amount of creatinine in the blood, and the Kidney Disease Improving Global Outcomes (KDIGO) classification system is considered as the standard for GFR measurement and diagnosis of CKD (Levin et al., 2013).
This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CKD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed and total prevalent cases of CKD. The diagnosed and total prevalent cases of CKD are segmented by age (18 years and older), sex, and stage. The diagnosed prevalent cases of CKD are segmented based on dialysis-dependent and non-dialysis-dependent cases. The dialysis dependent cases are further segmented by hemodialysis-dependent and peritoneal dialysis-dependent. Additionally, the diagnosed prevalent cases of CKD were further segmented by hyperparathyroidism, hyperphosphatemia, and hyperkalemia among dialysis-dependent and non-dialysis-dependent cases. This epidemiology forecast for CKD is supported by data obtained from peer-reviewed articles and population-based studies:
- The CKD epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
- The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies.
- Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.
Reasons to Buy
The CKD Epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global CKD market.
- Quantify patient populations in the global CKD market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups that present the best opportunities for CKD therapeutics in each of the markets covered.
- Understand magnitude of CKD by stage, hemodialysis-dependent and peritoneal dialysis-dependent; hyperparathyroidism, hyperphosphatemia, and hyperkalemia among dialysis-dependent and non-dialysis-dependent cases of CKD.
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.